690 related articles for article (PubMed ID: 25524795)
21. Anamorelin for cancer cachexia.
Nishie K; Sato S; Hanaoka M
Drugs Today (Barc); 2022 Mar; 58(3):97-104. PubMed ID: 35274629
[TBL] [Abstract][Full Text] [Related]
22. Treatment of cachexia: an overview of recent developments.
von Haehling S; Anker SD
J Am Med Dir Assoc; 2014 Dec; 15(12):866-72. PubMed ID: 25455531
[TBL] [Abstract][Full Text] [Related]
23. Prokinetics and ghrelin for the management of cancer cachexia syndrome.
Malik JS; Yennurajalingam S
Ann Palliat Med; 2019 Jan; 8(1):80-85. PubMed ID: 30525771
[TBL] [Abstract][Full Text] [Related]
24. [Efficacy of Anamorelin for the Treatment of Cancer Cachexia and Factors Associated with Weight Gain].
Okuda Y; Saitoh T; Mikame Y; Shinada M; Fujimura S; Suga R; Kobayashi N; Nakata M; Arai D; Nakazawa T; Yamaguchi H; Imai Y
Gan To Kagaku Ryoho; 2024 May; 51(5):529-533. PubMed ID: 38881063
[TBL] [Abstract][Full Text] [Related]
25. Real-world safety and effectiveness of anamorelin for cancer cachexia: Interim analysis of post-marketing surveillance in Japan.
Takayama K; Kojima A; Honda C; Nakayama M; Kanemata S; Endo T; Muro K
Cancer Med; 2024 May; 13(9):e7170. PubMed ID: 38693813
[TBL] [Abstract][Full Text] [Related]
26. Pharmacological management of cachexia in adult cancer patients: a systematic review of clinical trials.
Advani SM; Advani PG; VonVille HM; Jafri SH
BMC Cancer; 2018 Nov; 18(1):1174. PubMed ID: 30482179
[TBL] [Abstract][Full Text] [Related]
27. Usage of megestrol acetate in the treatment of anorexia-cachexia syndrome in the elderly.
Yeh SS; Lovitt S; Schuster MW
J Nutr Health Aging; 2009 May; 13(5):448-54. PubMed ID: 19390752
[TBL] [Abstract][Full Text] [Related]
28. [Pharmacological profile and clinical efficacy of anamorelin HCl (ADLUMIZ
Nakanishi Y; Higuchi J; Honda N; Komura N
Nihon Yakurigaku Zasshi; 2021; 156(6):370-381. PubMed ID: 34719572
[TBL] [Abstract][Full Text] [Related]
29. Skeletal muscle anabolism in patients with advanced cancer.
Baracos VE
Lancet Oncol; 2015 Jan; 16(1):13-4. PubMed ID: 25524803
[No Abstract] [Full Text] [Related]
30. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study.
Gotlieb WH; Amant F; Advani S; Goswami C; Hirte H; Provencher D; Somani N; Yamada SD; Tamby JF; Vergote I
Lancet Oncol; 2012 Feb; 13(2):154-62. PubMed ID: 22192729
[TBL] [Abstract][Full Text] [Related]
31. Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia.
Fearon KC; Barber MD; Moses AG; Ahmedzai SH; Taylor GS; Tisdale MJ; Murray GD
J Clin Oncol; 2006 Jul; 24(21):3401-7. PubMed ID: 16849754
[TBL] [Abstract][Full Text] [Related]
32. An overview of anamorelin as a treatment option for cancer-associated anorexia and cachexia.
Fonseca GWPD; von Haehling S
Expert Opin Pharmacother; 2021 May; 22(7):889-895. PubMed ID: 33491505
[TBL] [Abstract][Full Text] [Related]
33. A randomized, double-blind, placebo-controlled clinical trial of megestrol acetate as an appetite stimulant in children with weight loss due to cancer and/or cancer therapy.
Cuvelier GD; Baker TJ; Peddie EF; Casey LM; Lambert PJ; Distefano DS; Wardle MG; Mychajlunow BA; Romanick MA; Dix DB; Wilson BA
Pediatr Blood Cancer; 2014 Apr; 61(4):672-9. PubMed ID: 24167059
[TBL] [Abstract][Full Text] [Related]
34. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
[TBL] [Abstract][Full Text] [Related]
35. Anticachectic efficacy of megestrol acetate at different doses and versus placebo in patients with neoplastic cachexia.
Vadell C; Seguí MA; Giménez-Arnau JM; Morales S; Cirera L; Bestit I; Batiste E; Blanco R; Jolis L; Boleda M; Antón I
Am J Clin Oncol; 1998 Aug; 21(4):347-51. PubMed ID: 9708631
[TBL] [Abstract][Full Text] [Related]
36. Clinical studies on the treatment of cancer cachexia with megestrol acetate plus thalidomide.
Wen HS; Li X; Cao YZ; Zhang CC; Yang F; Shi YM; Peng LM
Chemotherapy; 2012; 58(6):461-7. PubMed ID: 23406994
[TBL] [Abstract][Full Text] [Related]
37. The regulatory approval of anamorelin for treatment of cachexia in patients with non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer in Japan: facts and numbers.
Wakabayashi H; Arai H; Inui A
J Cachexia Sarcopenia Muscle; 2021 Feb; 12(1):14-16. PubMed ID: 33382205
[TBL] [Abstract][Full Text] [Related]
38. Megestrol acetate for treatment of anorexia-cachexia syndrome.
Ruiz Garcia V; López-Briz E; Carbonell Sanchis R; Gonzalvez Perales JL; Bort-Marti S
Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD004310. PubMed ID: 23543530
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of anamorelin in patients with cancer cachexia: Post-hoc subgroup analyses of a placebo-controlled study.
Takayama K; Takiguchi T; Komura N; Naito T
Cancer Med; 2023 Feb; 12(3):2918-2928. PubMed ID: 36394148
[TBL] [Abstract][Full Text] [Related]
40. Randomised phase III clinical trial of 5 different arms of treatment on 332 patients with cancer cachexia.
Mantovani G
Eur Rev Med Pharmacol Sci; 2010 Apr; 14(4):292-301. PubMed ID: 20496538
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]